LLY vs NVO
GLP-1 leaders. Compare price, valuation, growth, profitability, and balance-sheet quality — all in one view.
Highlighted values indicate the better reading for that metric, where direction is unambiguous. Lower is generally better for valuation multiples and leverage; higher is better for growth, margin, and cash-flow metrics. Educational data only, not investment advice.
Next research paths
Open the full LLY stock page with chart, fundamentals, FAQ, and news context.
Open the full NVO stock page with chart, fundamentals, FAQ, and news context.
Check the next earnings date and reporting history for LLY.
Move from side-by-side comparison into open desk notes and live market context.
LLY vs NVO — common questions
Is LLY or NVO the better stock?
Across the valuation, growth, and profitability metrics compared on this page, NVO shows the stronger reading on more of them (9 vs 4). A metric tally is not a recommendation — the right pick depends on your time horizon and risk tolerance.
Which is bigger, LLY or NVO?
LLY has the larger market capitalization — LLY is about $1.08T versus $212.8B for NVO.
Which grows faster, LLY or NVO?
LLY shows the faster year-over-year revenue growth — LLY at 55.5% versus 24.0% for NVO.
Is LLY or NVO cheaper?
On forward price-to-earnings, NVO trades at the lower multiple — LLY at 27.2x versus 14.6x for NVO.
What is the difference between LLY and NVO?
Eli Lilly and Company operates in the Healthcare sector, while Novo Nordisk A/S operates in the Healthcare sector. This page compares the two across price, valuation multiples, growth, margins, and balance-sheet quality.
Go deeper than a side-by-side.
Add LLY and NVO to your Meridian watchlist for live alerts, AI-driven setups, and full earnings coverage.